Plain-English translation of NCT03587844 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing at lower doses than currently approved to see if it can treat certain rare skin lymphomas effectively while causing fewer side effects. Researchers want to find the best dose that works well without being too hard on your body. The study is looking at two groups: people who have never received this medication before, and people who have received it in the past.
The standard dose of this medication can sometimes cause serious side effects, particularly nerve damage. By testing lower doses, doctors hope to find a dose that still fights the cancer effectively but is gentler and easier to tolerate over time.
You likely qualify if…
You likely don't qualify if…
You would receive as an injection at a dose carefully chosen for your group. The study started at a lower dose (0.9 mg/kg) but has moved to 1.2 mg/kg based on early results. You would visit the hospital regularly for treatment and monitoring, and doctors will watch closely for side effects. If you have significant delays in treatment due to toxicity lasting more than 8 weeks, you may be removed from the study to protect your safety.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States